Insider Selling: Tempus AI (NASDAQ:TEM) EVP Sells $443,912.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 7,927 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $56.00, for a total transaction of $443,912.00. Following the completion of the sale, the executive vice president owned 138,140 shares in the company, valued at approximately $7,735,840. This trade represents a 5.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28.

Tempus AI Stock Performance

Tempus AI stock opened at $72.69 on Friday. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $13.12 billion, a P/E ratio of -50.48 and a beta of 3.58. The stock’s 50 day moving average is $52.93 and its 200 day moving average is $51.36.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the previous year, the business earned ($0.22) earnings per share. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. On average, equities research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TEM. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares in the last quarter. ARK Investment Management LLC increased its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after buying an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in Tempus AI in the 4th quarter worth about $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its position in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares during the last quarter. Finally, Amova Asset Management Americas Inc. raised its position in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Analyst Ratings Changes

TEM has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. HC Wainwright reduced their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. BTIG Research lifted their target price on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, Stifel Nicolaus cut their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.